Radiation biology research: protons, carbon ions and other particles
Location:WMI Level 2 Seminar room
Introduction by Dr Verity Ahern, Westmead Hospital:
‘Particle radiation therapy and why Australia should have a national treatment and research facility’
Associate Professor Marianne Nordsmark, MD, PhD
Department of Oncology, Aarhus University Hospital, Denmark
'Opportunities in radiation research in the perspective of a particle treatment centre'
Associate Professor Hany Elsaleh
ANU College of Medicine, Biology and Environment and
Director of Radiation Oncology at The Canberra Hospital
'Radiation biology research in Australia'
Lunch will be provided at 1pm
A/Prof Nordsmark is a clinical staff specialist and researcher in experimental radiotherapy and translational oncology at Aarhus University in Denmark. She recently initiated an international collaboration on miRNA prediction of chemo-radiotherapy response in gastro-esophageal cancer and the influence of tumour hypoxia on miRNA mechanisms and prediction of chemotherapy response in soft tissue sarcomas. Since 1991 Marianne has studied tumour hypoxia in human solid tumours using a range of hypoxia marker assays - lately gene array profiling based on serum and tumour biological material from a range of solid tumours, and relating these findings to treatment outcomes. Other programmes she is involved with include clinical development and implementation of PET hypoxia tracers, including modeling approaches interpreting and quantifying such PET hypoxia data calming for hypoxia prediction and targeting during radiotherapy.
A/Prof Elsaleh gained his PhD in molecular biology investigating DNA repair and chromosomal instability. He then was recruited to the David Geffen School of Medicine at the University of California Los Angeles as a Radiation Oncologist specialising in Gastrointestinal Malignancies. In Canberra he established a cancer research radiation biology laboratory program investigating clonogenic radiation sensitisation, in vivo tissue damage and recovery as well as novel clinical research in radiation reactions and targeted tissue recovery.